On February 9, 2021 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that collaboration partner SOTIO has stopped the combination trial assessing the combination of ONCOS-102 and DCVAC/PCa in prostate cancer (Press release, Targovax, FEB 9, 2021, View Source [SID1234574767]). Only a very limited patient population fulfilled the strict inclusion criteria. Therefore, the recruitment could not meet originally planned numbers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The phase I trial prostate cancer study was paid for and run by the Czech biotech company SOTIO, investigating whether ONCOS-102 could enhance the efficacy of SOTIO´s dendritic cell vaccine DCVAC/PCa. Targovax has generated promising data in melanoma and mesothelioma, and the decision will not impact the further development of ONCOS-102.

Patient recruitment has been slow due to limited patient population availability. In combination with additional COVID-19 related challenges, SOTIO has decided to stop the trial after four patients enrolled. This was a phase I safety trial, and an analysis of clinical outcomes will be submitted at a future scientific conference.